Dec. 24, 2008 | Vol. 6 No. 52
Cadence Pharmaceuticals reported positive results from a Phase III trial testing its injectable acetaminophen product Acetavance as a treatment for postoperative pain.
After reviewing safety data of Synta Pharmaceuticals’ Phase III trial of elesclomol in metastatic melanoma, an independent data monitoring committee recommended the trial continue.
Takeda Pharmaceutical has started a Phase III clinical study of ATL-962, a treatment for obesity and related diseases.
Supernus Pharmaceuticals has begun a pivotal Phase III clinical trial testing Epliga as a treatment for epileptic seizures.
ARYx Therapeutics’ oral arrhythmia therapy ATI-2042 met the primary endpoint in a Phase IIb clinical trial, reducing the incidence of atrial fibrillation, according to the biotech company.
Cytokinetics received encouraging data from a Phase IIa clinical trial evaluating the safety of CK-1827452 in patients with ischemic cardiomyopathy and angina.
CrystalGenomics and CG Pharmaceuticals received positive results from a Phase IIa study of CG100649 as a treatment for osteoarthritis.
SciClone Pharmaceuticals has begun enrolling patients in its Phase II study of SCV-07 for the prevention of oral mucositis in patients with head and neck cancer who receive radio-chemotherapy.
Based on data from Phase II trials, BioCryst Pharmaceuticals will continue its Forodesine HCl program in patients with chronic lymphocytic leukemia (CLL).
Cognition Pharmaceuticals received mixed results from a Phase II trial of testing C105 in multiple sclerosis (MS) patients with cognitive dysfunction.
Sucampo Pharma has started dosing patients in a Phase I study of its proprietary prostone, SPL-017, as a potential treatment for peripheral arterial disease.
Memory Pharmaceuticals received encouraging outcomes from its Phase I studies of R4996/MEM 63908, a drug being developed in collaboration with Roche for cognitive disorders such as Alzheimer’s disease.
A Phase I trial of Celgene and Acceleron Pharma’s ACE-011 produced promising findings for the treatment of bone complications.
Almost four months after GlaxoSmithKline (GSK) returned its rights to Adolor’s Entereg for the treatment of opioid bowel dysfunction (OBD), Adolor says it is halting development for the indication.
Abbott Laboratories won clearance to market its cholesterol drug TriLipix, the first fibrate to be combined with a statin for treating unhealthy cholesterol levels, the company says.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.